{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:24Z","timestamp":1763018424449,"version":"3.40.5"},"reference-count":7,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IMCRJ"],"DOI":"10.2147\/imcrj.s336259","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:10:13Z","timestamp":1637838613000},"page":"815-817","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Bahru","family":"Mantefardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6876-2904","authenticated-orcid":true,"given":"Gizaw","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5588\/ijtld.14.0535","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1701778","DOI":"10.1183\/13993003.01778-2017","volume":"51","author":"Heysell","year":"2018","journal-title":"Eur Respir J"},{"key":"ref3","unstructured":"Isabel JGA, Miroslava FP, Rafael LL. Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Available from: http:\/\/www.ramr.org\/articulos\/volumen_19_numero_3\/articulos_originales\/articulos_originales_second_line_injectable_drugs_for_the_treatment_of_multidrug-resistant_tuberculosis_why_do_we_keep_using_them.pdf. Accessed November 22, 2021."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0036-7","volume":"16","author":"Sagwa","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jinf.2021.05.010","volume":"83","author":"Dillard","year":"2021","journal-title":"J Infect"},{"key":"ref6","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.24041\/ejmr2020.45","volume":"7","author":"Baqar","year":"2020","journal-title":"Era\u2019s J Med Res"}],"container-title":["International Medical Case Reports Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=76186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=76186","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:10:15Z","timestamp":1637838615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/case-report-kanamycin-ototoxicity-and-mdr-tb-treatment-regimen-peer-reviewed-fulltext-article-IMCRJ"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":7,"URL":"https:\/\/doi.org\/10.2147\/imcrj.s336259","relation":{},"ISSN":["1179-142X"],"issn-type":[{"type":"electronic","value":"1179-142X"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}